328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis-Reference-Cited by-同舟云学术

328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis

Published:2018-05 Issue:6 Volume:154 Page:S-82
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Faleck David,Shashi Preeti,Meserve Joseph,Rahal Mahmoud,Kadire Siri,Tran Gloria,Weiss Aaron,Winters Adam,Chablaney Shreya,Aniwan Satimai,Koliani-Pace Jenna L.,Kochhar Gursimran,Boland Brigid S.,Singh Siddharth,Hirten Robert,Shmidt Eugenia,Lasch Karen,Luo Michelle,Bohm Matthew,Sagi Sashivar,Fischer Monika,Hudesman David,Chang Shannon,Lukin Dana J.,Keith Sultan,Swaminath Arun,Gupta Nitin,Siegel Corey A.,Shen Bo,Sandborn William J.,Sands Bruce E.,Colombel Jean Frederic,Kane Sunanda V.,Loftus Edward V.,Dulai Parambir

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Inflammatory Effects Of Calcitriol-Treated Mesenchymal Stem Cells On Experimental Ulcerative Colitis;Russian Open Medical Journal;2021-12-30

2. Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers;Alimentary Pharmacology & Therapeutics;2020-12-19

3. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis;Clinical Gastroenterology and Hepatology;2020-09

4. Positioning Therapies in the Management of Crohn’s Disease;Clinical Gastroenterology and Hepatology;2020-05